- New tariffs target broad sectors but exclude pharmaceuticals from China trade deal.
- Pharmaceutical companies face uncertainty despite broader trade restrictions.
- Sector-specific tariffs may follow, with healthcare innovation a potential focus.
Pharmaceuticals Left Out of China Trade Agreement
President Trump's recent trade measures with China notably exclude pharmaceuticals from the new reciprocal tariff agreement, leaving the sector in regulatory limbo. While a sweeping 34% tariff now applies to most Chinese imports, pharmaceutical products remain outside this framework - for now.
"We're looking at each industry individually," said a senior administration official who requested anonymity because discussions are ongoing. "Healthcare requires a different approach." The exclusion comes as the White House prepares additional sector-specific tariffs under Section 232 of the Trade Expansion Act.
Industry Reaction Mixed
Pharmaceutical executives expressed cautious relief at the exclusion but remain wary of future measures. "It gives us breathing room," said one major drugmaker's government relations head, speaking on background. "But we're still preparing for potential supply chain disruptions."
The administration's healthcare policy team has signaled interest in spurring biopharmaceutical innovation, particularly in personalized medicine. This focus may explain the temporary reprieve from tariffs, though multiple sources confirm pharmaceutical-specific trade measures are under consideration.
What Comes Next
With existing fentanyl tariffs already straining US-China pharmaceutical trade, companies are bracing for possible changes. The White House hasn't specified when - or if - drug tariffs might come, leaving industry groups scrambling to influence policy.
One thing is clear: while other sectors face immediate 34% duties, pharmaceuticals remain in regulatory purgatory - for now. As one lobbyist put it: "This isn't protection, it's prolonging the uncertainty."